Cerus Corp (CERS) - Forward Price-to-Revenue Multiple

cerus.com (CERS) - corporate logo

Strategic partnerships with clinics and blood centers are accelerating the expansion of Intercept systems. The forward P/S metric visualizes this process, with the parameter reaching 1.80. A monopoly status in plasma sterilization allows Cerus Corporation (CERS) to exercise pricing power, although high dependence on a single product creates risks associated with the pace of platform implementation in new hospitals.

CERS cerus.com: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/16/2026

Cerus - analytical breakdowns and key metrics (CERS)

- market price and analyst price targets:
- market capitalization indicators:
General company analysis:CERS (Cerus Inc)
Original product of cerus.com

The market audit of Cerus Corporation (CERS) is based on the valuation of its unique pathogen inactivation systems relative to expected revenue. By analyzing the forward P/S trajectory, an investor determines the premium paid for future sales, which allows for a comparison of current market capitalization against the expansion potential of critical blood safety technologies and confirms the fundamental resilience of the business.

Analysis of competing companies

Price-to-Projected Revenue Ratio Intuitive Surgical Inc ISRG|Forward P/S Multiple Danaher Corporation Inc. DHR|BDX - Price-to-Projected Revenue Ratio|STERIS plc (STE) - Forward Price-to-Revenue Multiple|WST: Forward P/S Multiple|Market Cap to Future Revenue Ratio Baxter International Inc. (BAX)|MASI (masimo.com) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group Corp STVN|Forward Price-to-Revenue Multiple TFX (Teleflex Inc)|Merit Medical - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (ICU Medical Inc)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Corp LMAT|ATRC: Forward P/S Multiple|STAA - Market Cap to Expected Sales Ratio|NAGE (Chromadex Corp) - Forward P/S Multiple|ZimVie Inc (ZIMV) - Market Cap to Expected Sales Ratio|Forward P/S Multiple ANGO|TKNO: Future Price to Revenue|Price-to-Projected Revenue Ratio Monogram Technologies Inc. MGRM|Forward Price to Sales STSS|INFU - Price-to-Projected Revenue Ratio|Forward Price to Sales UTMD (Utah Medical Products Inc.)|KORU Medical Systems Inc. (KRMD) - Price-to-Projected Revenue Ratio|Nyxoah S.A. - Forward Price to Sales|Price-to-Projected Revenue Ratio Microbot Medical, Inc.|Market Cap to Projected Revenue PDEX (Pro-Dex)|Price-to-Projected Revenue Ratio Zentek (ZTEK)|Market Cap to Expected Sales Ratio Elutia Inc|Forward P/S Multiple MLSS (milestonescientific.com)|NXGL: Market Cap to Projected Revenue|Retractable Tech - Forward P/S Multiple|Market Cap to Expected Sales Ratio Harvard Bioscience Inc. HBIO|FEMY: Forward P/S Multiple|MeihuaMed - Forward Price to Sales|Price-to-Projected Revenue Ratio Predictive Oncology Inc|callanjmb.com (CJMB) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Atrion Corporation (ATRI)|Market Cap to Expected Sales Ratio neurometrix.com